share_log

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

阿童木健康發佈2024年至2027年更新指引,預計到2027年每年營業收入爲15580萬美元,調整後EBITDA爲2940萬美元,這是由於對高利潤領域的戰略重點推動的。
Accesswire ·  09/19 01:30

CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its updated guidance for the 2024-2027 period.

芝加哥,伊利諾伊州/ACCESSWIRE/2024年9月18日/Cosmos Health Inc.("Cosmos Health"或"公司")(納斯達克股票代碼:COSM)是一家多元化、垂直一體化的全球醫療集團,從事創新的研發,擁有專有的藥品和保健品品牌,生產和分銷醫療產品,並經營遠程醫療平台,今日宣佈了其2024-2027年期間的更新指引。

Key highlights of the guidance include:

指引的重點包括:

  • Revenue is projected to increase by 163%, from $59.35 million in 2024 to $155.80 million in 2027.

  • Gross profit is expected to rise by 653%, from $6.25 million in 2024 to $47.06 million in 2027.

  • Gross profit margin is anticipated to expand by 1,970 basis points, from 10.50% in 2024 to 30.20% in 2027.

  • Net income is projected to increase by 402%, reaching $20.44 million in 2027, from a loss of $6.76 million in 2024.

  • Adjusted EBITDA is expected to grow to $29.40 million in 2027, from a loss of $1.21 million in 2024.

  • 預計營業收入將從2024年的5935萬美元增加163%,至2027年的15580萬美元。

  • 毛利潤預計將從2024年的625萬美元增長653%,至2027年的4706萬美元。

  • 毛利潤率預計將擴大1970個點子,從2024年的10.50%擴展至2027年的30.20%。

  • 淨利潤預計將增長402%,從2024年的676萬美元虧損,提升至2027年的2044萬美元。

  • 調整後的EBITDA預計將從2024年的121萬美元虧損增長至2027年的2940萬美元。

The above achievements are expected to stem from a combination of strategic factors, including a focus on higher-margin business segments, operational synergies, and improved cost efficiency. Specifically, the Company will prioritize the following initiatives, among others:

上述成就預計將源自一系列戰略因素,包括專注於較高利潤率的業務板塊、運營協同效應和成本效率的提高。具體來說,公司將優先考慮以下倡議,以及其他:

  • Expansion of Sky Premium Life's geographical footprint and product portfolio, with the introduction of new formulas, therapeutic areas, and customized offerings, supported by strategic partnerships with exclusive distributors and digital channels.

  • The global launch of C-sept and C-scrub, both with significant market potential and limited competition. Production is being scaled up, with additional products in development.

  • Expansion of generic pharmaceuticals across the EU and other international markets, with a focus on advanced generics and innovative OTC products.

  • Optimization of Contract Manufacturing Organization (CMO) operations, with a focus on high-demand medicines and competitive pricing.

  • Progress toward World Medical Organization (WMO) patent approval and completion of clinical trials for the CCX obesity pill by 2025, with commercialization expected in 2026.

  • Driving organic growth and integrating the pharmacy distribution network for enhanced efficiency and scalability.

  • Corporate reorganization focused on cost-cutting initiatives and optimizing asset and resource utilization through the integration of business units.

  • 擴大Sky Premium Life的地理範圍和產品組合,引入新配方、治療領域和定製產品,通過與獨家經銷商和數字渠道的戰略合作支持。

  • 全球推出C-sept和C-scrub,兩者都具有顯着的市場潛力和有限的競爭。生產正在擴大規模,同時還在開發其他產品。

  • 在歐盟和其他國際市場擴大普通藥品業務,專注於先進的仿製藥和創新的場外交易產品。

  • 優化承包生產組織(CMO)運營,專注於高需求藥品和競爭性定價。

  • 朝着2025年取得世界醫學組織(WMO)專利批准並完成CCX減肥藥臨床試驗的進展,預計於2026年開始商業化。

  • 推動有機增長,並整合藥店分銷網絡以提高效率和可擴展性。

  • 通過整合業務單元,進行以削減成本爲重點的企業重組,優化資產和資源利用。

The complete guidance is outlined in the table below.

完整的指導信息已在下表中概述。

($)

2024

2025

2026

2027

Revenue

59,349,546

80,670,924

125,124,323

155,802,733

Gross profit

6,251,422

16,208,325

32,120,201

47,061,142

Gross profit margin (%)

10.50%

20.10%

25.70%

30.20%

Income / (loss) from operations

-6,376,828

2,881,375

15,280,227

26,629,633

Income / (loss) before income taxes

-6,761,998

2,290,791

14,815,306

26,209,497

Net income / (loss)

-6,761,998

1,786,817

11,555,939

20,443,407

Adjusted EBITDA

-1,205,344

6,269,028

19,604,785

29,397,406

Adjusted EBITDA margin (%)

-2.00%

7.80%

15.70%

18.90%

YoY Revenue Growth

11.20%

35.90%

55.10%

24.50%

YoY Gross Profit Growth

43.70%

159.30%

98.20%

46.50%

YoY Net Income Growth

63.50%

126.40%

546.70%

76.90%

YoY Adj EBITDA Growth

-99.80%

620.10%

212.70%

50.00%

($)

2024

2025

2026

2027

營業收入

59,349,546

80,670,924

125,124,323

155,802,733

毛利潤

6,251,422

16,208,325

32,120,201

47,061,142

Gross profit margin (%)

10.50%

20.10%

25.70%

30.20%

營業收入/(虧損)

-6,376,828

2,881,375

15,280,227

26,629,633

稅前收益/損失

-6,761,998

2,290,791

14,815,306

26,209,497

淨利潤 / (損失)

-6,761,998

1,786,817

11,555,939

20,443,407

調整後的EBITDA

-1,205,344

6,269,028

19,604,785

29,397,406

調整後的EBITDA利潤率(%)

-2.00%

7.80%

15.70%

18.90%

YoY Revenue Growth

11.20%

35.90%

55.10%

24.50%

同比毛利潤增長

43.70%

159.30%

98.20%

46.50%

同比淨利潤增長

63.50%

126.40%

546.70%

76.90%

YoY Adj EBITDA Growth

-99.80%

620.10%

212.70%

50.00%

Greg Siokas, CEO of Cosmos Health, stated: "Cosmos is at a critical inflection point, and I am delighted to share with our shareholders more detailed guidance for the period 2024 to 2027. We are laser-focused on expanding our revenue base through high-margin segments such as CMO operations and the global growth of our proprietary brands, while also emphasizing efficiencies and cost-cutting initiatives. As a result, we now expect to be profitable and generate significant positive operating cash flow starting in 2025.

Cosmos Health的CEO Greg Siokas表示:"Cosmos正處於關鍵的轉折點,我很高興與股東分享2024年至2027年期間更詳細的指引。我們將集中精力通過CMO運營和我們自有品牌在全球增長這種高利潤率領域來擴大收入基礎,同時也強調效率和削減成本的舉措。因此,我們預計從2025年開始實現盈利,併產生顯著的正面經營現金流。"

By 2027, we anticipate adjusted EBITDA to reach approximately $30 million annually, with net income surpassing $20 million. This should have a tremendously positive impact on our balance sheet, positioning us to self-fund our growth aspirations and reward our shareholders."

到2027年,我們預計調整後的EBITDA每年將達到約$3000萬,淨利潤超過$2000萬。這將對我們的資產負債表產生巨大的正面影響,使我們能夠自行實現增長願望並回報股東。"

The Company provides EBITDA guidance that may not include certain charges and costs, which in future periods are generally expected to be similar to the kinds of charges and costs excluded from EBITDA in prior periods, such as income taxes, interest and other non-operating items, depreciation and amortization, net unrealized gains and losses on derivatives, lower of cost or net realizable value adjustments, gains and losses on disposal or impairment of assets, gains and losses on early extinguishment of liabilities, equity-based compensation expense, acquisition expense, revaluation of liabilities and items that are extraordinary or non-recurring, foreign currency transactions, net and prior years bad debt allowance. The exclusion of these charges and costs in future periods may have a significant impact on the Company's EBITDA, and the Company may not be able to provide a reconciliation of its EBITDA guidance to net income (loss) without unreasonable efforts due to the uncertainty and variability of the nature and amount of these future charges and costs and the Company believes that such reconciliation, if possible, would imply a degree of precision that would be potentially confusing or misleading to investors.

公司提供的EBITDA指引可能不包括某些費用和成本,在未來期間通常預計與以前期間在EBITDA中排除的類型的費用和成本相似,例如所得稅、利息和其他非運營項目、折舊和攤銷、衍生工具淨未實現收益和損失、成本或淨可變現價值調減、資產處置或減值的收益和損失、提前清償負債的收益和損失、權益計量補償費用、收購費用、負債重新評估以及其異常或非經常發生的項目、外幣交易、淨和往年壞賬準備。在未來期間排除這些費用和成本可能會對公司的EBITDA產生重大影響,由於未來這些費用和成本的性質和數量的不確定性和可變性,公司可能無法通過不合理的努力提供其EBITDA指引與淨利潤(損失)的調和,公司認爲如果可能,這種調和可能會暗示一種潛在令投資者感到困惑或誤導的精確度水平。"

About Cosmos Health Inc.

Cosmos Health Inc.(納斯達克:COSM)成立於2009年,總部位於內華達州,是一家全球健康醫療集團公司。公司擁有一系列專有藥品和保健品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.獲得歐洲GMP許可和歐洲藥品管理局認證,生產醫藥品、食品補充劑、化妝品、生物滅菌劑和醫療設備等產品,並經營歐盟內的銷售。此外,Cosmos Health還通過希臘和英國的子公司向零售藥店和批發經銷商銷售廣泛的藥品和非處方藥品,包括品牌仿製藥和OTC藥品。此外,該公司還與人工智能藥物再利用技術合作,專注於研發針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作,並專注於研發新的專利營養保健品、特殊植物提取物、專有複合仿製藥和創新非處方藥品。Cosmos Health還通過收購總部位於德克薩斯州的ZipDoctor,Inc進入了遠程醫療領域。公司正在全球範圍內擴張,並在希臘的塞薩洛尼基和雅典、英國的哈洛等地設有辦事處和配送中心。 更多信息請訪問公司網站:,以及LinkedIn和X。

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.

Cosmos Health公司(Nasdaq:COSM)成立於2009年,總部位於內華達州,是一家多元化、垂直一體化的全球醫療保健集團,擁有一系列專有藥品和營養保健品品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。通過其子公司Cana Laboratories S.A.,該公司生產製藥、食品補充劑、化妝品、生物農藥和醫療設備等,持有歐洲藥品管理局(EMA)頒發的歐洲GMP證書,滿足GMP標準。Cosmos Health公司還通過旗下位於希臘和英國的子公司向零售藥店和批發商銷售廣泛的藥品和非藥品醫療產品。此外,該公司還建立了針對肥胖症、糖尿病和癌症等重大健康問題的研發夥伴關係,加強人工智能藥物再利用技術,專注於研發新型專利營養保健品、特殊根部提取物、專有複雜化學品和創新的非處方產品。Cosmos Health公司還通過收購總部位於美國德克薩斯州的ZipDoctor公司進入了遠程醫療領域。

Forward-Looking Statements

前瞻性聲明

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Cosmos Health Inc.("公司")在本新聞稿中所述的事項中除了包含歷史信息外,還可能包含根據1933年修訂的《證券法》第27A條和1934年修訂的《證券交易法》第21E條的前瞻性陳述。前瞻性聲明涉及未知的風險和不確定性,可能因以下原因之一而對討論的事項產生個別或實質性影響,這在公司的控制範圍之外,包括但不限於公司籌集足夠融資實施其業務計劃的能力,新冠病毒大流行和烏克蘭戰爭對公司業務、運營和經濟的影響以及公司成功開發和商業化自有產品和技術的能力。讀者應該注意不要過度依賴這些前瞻性聲明,因爲實際結果可能與本新聞稿中所述的前瞻性聲明不同。讀者應該注意閱讀證券交易委員會的風險因素,該委員會在其網站上(www.sec.gov)提供了這些信息。本公司不承擔更新或修訂任何前瞻性陳述的義務。

Investor Relations Contact:

投資者關係聯繫人:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

資訊來源:Cosmos Health Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論